Inflammatory Bowel Disease
Extended treatment with Skyrizi ‘may ultimately benefit’ refractory Crohn’s disease
Patients with moderate to severe Crohn’s disease who did not achieve clinical response to IV induction with Skyrizi benefitted from an additional 12 weeks of treatment, according to study results in Clinical Gastroenterology and Hepatology.
Tremfya’s FDA win as fully subcutaneous option for Crohn’s may pave way to eclipse Stelara
The FDA has approved Tremfya as the “first and only” interleukin-23 inhibitor that offers both IV and fully subcutaneous induction options for the treatment of moderately to severely active Crohn’s disease, Johnson & Johnson reported.
Etrasimod can be safely used alongside opioids, antidepressants in ulcerative colitis
Using etrasimod with opioids or antidepressants did not increase risk for serotonin syndrome-associated adverse events among patients with ulcerative colitis, according to a study published in United European Gastroenterology Journal.
Q&A: Wearable devices may help IBD patients track flares in ‘the comfort of their homes’
Physiological metrics captured via wearable devices may help identify and predict flares in inflammatory bowel disease, Robert P. Hirten, MD, told Healio, and could potentially play a role in remote monitoring of disease activity.
Q&A: ‘Everyone benefits’ from noninvasive, individualized monitoring in pediatric IBD
SAN FRANCISCO — Noninvasive monitoring methods, such as enterography and ultrasound, are becoming increasingly recognized as essential tools in the management of pediatric patients with inflammatory bowel disease, according to presenters.
Oral vancomycin may offer ‘viable option’ for IBD-related primary sclerosing cholangitis
Oral vancomycin therapy resulted in clinical response in nearly half of patients with inflammatory bowel disease associated with primary sclerosing cholangitis, according to a study published in Therapeutic Advances in Gastroenterology.
VIVID-2: Omvoh demonstrates ‘continued durability,’ safety in Crohn’s disease at 2 years
SAN FRANCISCO — Most patients with moderately to severely active Crohn’s disease who achieved endoscopic response and remission after 52 weeks of Omvoh therapy maintained those results through 104 weeks, according to VIVID-2 study results.
Train support staff to be aware of mental health concerns in IBD to avoid future trauma
SAN FRANCISCO — Patients with inflammatory bowel disease remain at higher risk for mental health disorders, but training support staff to recognize the symptoms could be key to preventing further traumatization, noted a presenter here.
Most patients with IBD ‘still experience significant challenges’ accessing, affording care
SAN FRANCISCO — Despite advances in treatment for inflammatory bowel disease, more than 55% of patients report medication delays, mostly due to insurance challenges, and many make financial trade-offs to afford care, survey results showed.
‘Lack of patient activation’ in pediatric IBD may be poor health literacy in disguise
SAN FRANCISCO — Patient activation, earned trust and health literacy at patient, provider and health system levels are critical to overcoming health disparities among pediatric patients with inflammatory bowel disease, noted a presenter.